Humedics, based in Berlin, focuses on rapid and precise liver function measurement using LiMAx, its innovative breath analysis technology. This easy-to-use bedside test provides doctors with accurate information to support decision making in tailoring the medical treatment to the individual level of each patient and to improve patient outcomes.
LiMAx has already been used on thousands of patients and the company is currently expanding its operation globally.
Chief Executive Officer
Andrew Moore, a Swiss and British national, has been a member of the executive management team of medium-sized and small companies in the healthcare sector for almost 20 years. Previously, he worked in sales and finance in banking for more than 20 years in both London and Zurich.
Most recently, he was CFO at LifeWatch AG, a Swiss listed cardiac monitoring company which was acquired by a US competitor. Previously, he was CEO/CFO at several start-ups and Chief Investment Officer for two listed investment companies focusing on sustainable start-ups. Andrew´s experience includes raising finance, publishing a prospectus, overseeing several due diligence processes and successful selling companies.
He has a BSc. in Statistics and Operational Research from the University of Leeds and is a qualified English Chartered Accountant (FCA), qualified English Tax Advisor (CTA), certified European Financial Analyst (CEFA) and holds a Certificate in Corporate Governance from INSEAD.
Chief Mergers and Acquisitions Officer
Karsten Damgaard-Iversen, MBA
Karsten Damgaard-Iversen is an internationally accomplished business professional with over 30 years of global experience in the med-tech industry. He is a proven leader in operational and strategic management positions within large, medium and small healthcare technology companies.
Karsten combines strong leadership skills and business acumen with in-depth technical and medical knowledge. He has served as a Board Director at Toshiba of Europe Ltd., Managing Director and Chief Group Executive at Toshiba Medical Systems Europe BV, Managing Director at Toshiba Medical Systems UK Ltd., CEO at SonoCine Inc., VP of International Operations at Fisher Imaging Corporation and Director of Sales & Marketing at Storz Medical AG.
Karsten has also directly contributed to the invention and development of specific laser, ultrasound and x-ray based medical products. He holds an MBA from Emory University in Atlanta and a BSc in electronic engineering from Copenhagen University College.
Finance & Controlling Manager
Kajo Wiest is Finance Manager of the Humedics GmbH and brings more than 15 years of finance and controlling experiences.
He was Director Controlling at Jerini AG. During his time at Jerini, he was responsible for the establishment of controlling structures as well as supporting the company’s IPO and the sale of its wholly-owned subsidiary JPT, where he served as Finance Manager afterwards.
Before he joined Humedics he worked as Director Finance& Controlling for Magforce AG.
An engineer by passion, an entrepreneur at heart
As an entrepreneur and engineer, I have over 30 years of experience in corporate management and technology development in the MedTech field.
A common thread guides my career choices; combining innovation and strategy in order to match product benefits with the market’s requirements. With this purpose in mind, in 2003, bolstered by years of experience in health care, I created a start-up company in collaboration with my partners, known as Anteis.
By awarding, my contribution to the industry in 2008 in the “HIGH-TECH AND BIOTECH” category, the experts of the Swiss Economic Forum honored the exceptional services of Anteis in the following fields: innovation, creativity, quality of services, job creation, technological advantage, research and development, and more.
Within 10 years, through focus on developing, manufacturing and marketing injectable Hyaluronic Acid, Anteis became known as a global leader in this particular field. Anteis was acquired by Merz Pharma in 2013.
Since 2013, I have focused on the financing and development of SMEs in various sectors through our global platform, now known as Medaesthetis. I recognize in Medaesthetis a real capacity to propose new technologies for Medical and Aesthetic treatments. Contributing to the projects on a daily basis, I bring my vision and expertise helping the teams to give their best for the satisfaction of our partners and clients.
Thomas Moeller is a general partner of BioMedPartners AG, which focuses on investments in life sciences in the DACH region. Thomas has been a venture capitalist for the last 17 years. Before joining BioMedPartners in 2003, he worked as Chief Financial Officer at NMT New Medical Technologies and as a Senior Manager at PricewaterhouseCoopers in Switzerland and the United States. Mr. Moeller has a degree as Swiss certified public accountant in 1996 as well as a master degree in economics and business administration from the University of Basel in 1991.
Karsten Haesen is the CEO of Ventegis Capital AG, which invests in early stage and growth phase companies. He has more than 30 years of experience in the field of corporate financing. Before joining Ventegis Capital AG, he was project manager in corporate finance at Berliner Effektenbank AG (now Quirin Privatbank AG), where he was responsible for numerous IPOs and other equity financing transactions. Prior to this he worked for 7 years in the Corporate and Institutional Clients division at Deutsche Bank. Mr. Haesen is a board member of Berliner Effektengesellschaft AG and a member of the supervisory board of Tradegate AG Wertpapierhandelsbank, Berlin.
Dr. Annegret de Baey-Diepolder is a Venture Partner at Seventure Partners SA. Formerly she was co-founder and CEO of RNA-based immunotherapeutics company Rigontec GmbH, now Merck & Co., Inc..
As a life science industry consultant and former partner at private equity and venture capital companies TVM Capital and Gimv NV, she brings more than 15 years of experience in the life science and venture capital sector.
Dr. Christian Schneider is a managing partner of Vesalius Biocapital and has been a venture capital executive for more than 15 years, including time spent at PolyTechnos. He has worked in diagnostics, medtech, and therapeutics, including at Boehringer Mannheim/Roche, where he developed the first fully automated test for a new prostate cancer marker (free PSA), which is marketed by Roche worldwide.
Dr. Klaus Stoeckemann is a co-founder and managing partner of Peppermint VenturePartners, which focuses on investments in medical device and digital-health start-up companies in Germany and Europe. He is an experienced venture capitalist with more than 15 years of experience, including a role as a general partner at 3i Healthcare Venture Capital. Stoeckemann has also worked at Schering AG (now Bayer) and Asta Medica (Degussa), and is a member of the board of the German Association of Venture Capital (BVK).
Medical Advisory Board
|Prof. Dr. Peter Galle (Lead)|
|Prof. Dr. Hauke Lang|
|Prof. Dr. Guido Gerken|
|Prof. Dr. Hans J. Schlitt|
|Prof. Dr. Ali Canbay|
|Prof. Dr. Stefan Fichtner-Feigl|
Founders & Scientific Advisory Board
Karsten Heyne is one of the co-founders of Humedics GmbH. He is a Professor at the Free University of Berlin, with a focus on ultrafast spectroscopy in biologically-relevant systems. His research investigates electronic and structural changes as well as the specific manipulation of special organic molecule groups.
Martin Stockmann is one of the co-founders of Humedics GmbH, and continues to provide advice and support to the management team on medical-related issues. He is chief physician at the clinic for general, visceral and vascular surgery at the Evangelical Hospital Paul Gerhardt Stift in Wittenberg. He leads the Workgroup for the Liver, looking at improving recovery of patients after liver surgery and transplantation. Stockmann has published over 100 articles in the field of liver function testing.
Martin Stockmann, MD, PhD, an abdominal surgeon at the Berlin Charité University medical centre, created the LiMAx test in 2001 and founded the workgroup for the liver.
Karsten Heyne, a professor at the department of physics, Free University of Berlin, conducted the technical development of the LiMAx test.
Humedics was founded in 2009, and the company began development of the LiMAx prototype, with initial capital provided by the High Tech Gründerfonds. Today, Humedics has about 10 employees and scale up production development is ongoing. In May 2011, Humedics successfuly completed a second round of founding, with Charité Biomedical Fonds, KfW, VC Fonds Technologie Berlin and Ventegis Capital AG joining as investors.
Major award received in 2014